EXEL

Exelixis
D

EXEL

72.780
USD
0.46
(0.64%)
مغلق
آخر تحديث: · متأخرة 15 دقيقة
حجم التداول
104,687
الربح لكل سهم
3
العائد الربحي
-
P/E
22
حجم السوق
17,759,112,938
أصول ذات صلة

العنوان: Exelixis

القطاع: الرعاية الصحية
الصناعة: Biotechnology
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

أسئلة شائعة حول سهم Exelixis